Regenerex Pharma (RGPX) 10-Q 24 Jan 23 2022 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Dec. 31, 2022	Jan. 24, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2022
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--03-31
Entity File Number	000-53230
Entity Registrant Name	REGENEREX PHARMA, INC.
Entity Central Index Key	0001357878
Entity Tax Identification Number	98-0479983
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	5348 Vegas Drive #177
Entity Address, City or Town	Las Vegas
Entity Address, State or Province	NV
Entity Address, Postal Zip Code	89108
City Area Code	(702)
Local Phone Number	273-3772
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		277,112,660

BALANCE SHEETS (UNAUDITED)

BALANCE SHEETS (UNAUDITED) - USD ($)	Dec. 31, 2022	Mar. 31, 2022
Current Assets
Cash and equivalents	$ 1,203	$ 2,640
Prepaid expenses	2,500	5,256
Total Current Assets	3,703	7,896
Website, net of accumulated amortization of $25,690 and $23,174, respectively	4,910	7,426
Computer equipment, net of accumulated amortization of $82 and $0, respectively	1,316
Total Assets	9,929	15,322
Current Liabilities
Accounts payable	66,125	63,027
Related party advances	131,887	131,687
Accrued compensation	221,192	221,192
Other accrued liabilities	118,301	91,667
Current portion of notes payable to shareholder	337,369	152,880
Total Current Liabilities	874,874	660,453
Notes payable to shareholder, net of current portion	173,712	340,486
Notes payable to related parties	38,000
Total Liabilities	1,086,586	1,000,939
Stockholders’ Deficit
Common stock: $0.001 par value: 675,000,000 shares authorized: 277,112,660 issued and outstanding at December 31, 2022 and March 31, 2022	277,113	277,113
Additional paid-in capital	671,963	671,963
Accumulated deficit	(2,025,733)	(1,934,693)
Total Stockholders’ Deficit	(1,076,657)	(985,617)
Total Liabilities and Stockholders’ Deficit	$ 9,929	$ 15,322

BALANCE SHEETS (UNAUDITED) (Par

BALANCE SHEETS (UNAUDITED) (Parenthetical) - USD ($)	Dec. 31, 2022	Mar. 31, 2022
Statement of Financial Position [Abstract]
Finite-Lived Intangible Assets, Accumulated Amortization	$ 25,690	$ 23,174
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	$ 82	$ 0
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Common Stock, Shares Authorized	675,000,000	675,000,000
Common Stock, Shares, Issued	277,112,660	277,112,660
Common Stock, Shares, Outstanding	277,112,660	277,112,660

STATEMENTS OF OPERATIONS (UNAUD

STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021
Operating Expenses
General and administrative	$ 28,802	$ 61,975	$ 67,592	$ 94,737
Sales and marketing	300		300
Total Operating Expenses	29,102	61,975	67,892	94,737
Operating Loss	(29,102)	(61,975)	(67,892)	(94,737)
Other Income (Expense)
Interest expense	(17,241)	(14,548)	(49,365)	(44,130)
Foreign currency gain (loss)	(3,057)	(1,889)	26,217	483
Total Other Income (Expense)	(20,298)	(16,437)	(23,148)	(43,647)
Loss from Continuing Operations	(49,400)	(78,412)	(91,040)	(138,384)
Loss from Discontinued Operations		(1,022)		(8,758)
Net Loss	$ (49,400)	$ (79,434)	$ (91,040)	$ (147,142)
Basic and Diluted Loss per Common Share	$ 0	$ 0	$ 0	$ 0
Weighted Average Number of Common Shares Outstanding	227,112,660	203,743,095	277,112,660	152,749,024

STATEMENTS OF CASH FLOWS (UNAUD

STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)	9 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Cash Flows from Operating Activities:
Net loss	$ (91,040)	$ (147,142)
Loss from discontinued operations		8,758
Adjustments to reconcile net loss to cash flows used in operating activities:
Depreciation	2,598	2,329
Foreign currency adjustments	(26,217)	(483)
Stock-based compensation		45,000
Changes in operating assets and liabilities:
Prepaid expenses	2,756	1,213
Accounts payable and accrued liabilities	38,763	36,033
Net cash used in continuing operating activities	(73,140)	(54,292)
Net cash used in discontinued operating activities		(8,758)
Net cash used in operating activities	(73,140)	(63,050)
Cash Flows from Investing Activities:
Website		(8,600)
Computer equipment	(1,398)
Net cash used in investing activities	(1,398)	(8,600)
Cash Flows from Financing Activities:
Related party advances	200	455
Proceeds from notes payable to shareholder	34,901	67,082
Proceeds from notes payable to related parties	40,500
Partial repayment of note payable to related parties	(2,500)
Net cash provided by financing activities	73,101	67,537
Decrease in cash and equivalents	(1,437)	(4,113)
Cash and cash equivalents, beginning of period	2,640	6,902
Cash and cash equivalents, end of period	1,203	2,789
Supplemental Cash Flow Information – Cash Paid For:
Income Taxes
Interest
Non-Cash Investing and Financing Activities:
Accrued interest converted into note payable to shareholder	7,211	27,254
Shares issued for the acquisition of intellectual property		$ 150,000

STATEMENTS OF STOCKHOLDERS' DEF

STATEMENTS OF STOCKHOLDERS' DEFICIT (UNAUDITED) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Mar. 31, 2021	$ 127,113	$ 776,963	$ (1,739,102)	$ (835,026)
Common Stock, Shares, Outstanding, Beginning Balance at Mar. 31, 2021	127,112,660
Net Loss			(67,708)	(67,708)
Ending balance, value at Sep. 30, 2021	$ 127,113	776,963	(1,806,810)	(902,734)
Common Stock, Shares, Outstanding, Ending Balance at Sep. 30, 2021	127,112,660
Beginning balance, value at Mar. 31, 2021	$ 127,113	776,963	(1,739,102)	(835,026)
Common Stock, Shares, Outstanding, Beginning Balance at Mar. 31, 2021	127,112,660
Net Loss				(147,142)
Ending balance, value at Dec. 31, 2021	$ 277,113	671,963	(1,886,244)	(937,168)
Common Stock, Shares, Outstanding, Ending Balance at Dec. 31, 2021	277,112,660
Beginning balance, value at Sep. 30, 2021	$ 127,113	776,963	(1,806,810)	(902,734)
Common Stock, Shares, Outstanding, Beginning Balance at Sep. 30, 2021	127,112,660
Net Loss			$ (79,434)	$ (79,434)
Common stock issued for purchase of intellectual property	150,000	(150,000)
Stock Issued During Period, Shares, Purchase of Assets				150,000,000
Stock-based compensation		$ 45,000		$ 45,000
Ending balance, value at Dec. 31, 2021	$ 277,113	671,963	(1,886,244)	(937,168)
Common Stock, Shares, Outstanding, Ending Balance at Dec. 31, 2021	277,112,660
Beginning balance, value at Mar. 31, 2022	$ 277,113	671,963	(1,934,693)	$ (985,617)
Common Stock, Shares, Outstanding, Beginning Balance at Mar. 31, 2022	277,112,660			277,112,660
Net Loss			(41,640)	$ (41,640)
Ending balance, value at Sep. 30, 2022	$ 277,113	671,963	(1,976,333)	(1,027,257)
Common Stock, Shares, Outstanding, Ending Balance at Sep. 30, 2022	277,112,660
Beginning balance, value at Mar. 31, 2022	$ 277,113	671,963	(1,934,693)	$ (985,617)
Common Stock, Shares, Outstanding, Beginning Balance at Mar. 31, 2022	277,112,660			277,112,660
Net Loss				$ (91,040)
Ending balance, value at Dec. 31, 2022	$ 277,113	671,963	(2,025,733)	$ (1,076,657)
Common Stock, Shares, Outstanding, Ending Balance at Dec. 31, 2022	277,112,660			277,112,660
Beginning balance, value at Sep. 30, 2022	$ 277,113	671,963	(1,976,333)	$ (1,027,257)
Common Stock, Shares, Outstanding, Beginning Balance at Sep. 30, 2022	277,112,660
Net Loss			(49,400)	(49,400)
Ending balance, value at Dec. 31, 2022	$ 277,113	$ 671,963	$ (2,025,733)	$ (1,076,657)
Common Stock, Shares, Outstanding, Ending Balance at Dec. 31, 2022	277,112,660			277,112,660

NATURE OF OPERATIONS

NATURE OF OPERATIONS	9 Months Ended
	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
NATURE OF OPERATIONS	NOTE 1 – NATURE OF OPERATIONS Regenerex Pharma, Inc., formerly Peptide Technologies, Inc. (the “Company” or “Regenerex”), was incorporated in the State of Nevada, United States of America, on November 18, 2005. The Company’s business was to develop and market proprietary skincare products that was to be sold online. The majority of manufacturing, distribution, marketing, and sales operations was outsourced. The Company’s attempt over the past four years to build a business that marketed skincare products online has not come to fruition, so management decided to change the business focus and look for other opportunities. On November 15, 2021, the Company entered into an Asset Purchase Agreement in which the Company purchased certain intellectual property in exchange for 150,000,000 shares of the Company’s common stock and up to $10,000,000 in contingent consideration to be paid at the rate of 15% of all gross revenues received from sales or investment money into the Company, payable on the 15 th Management has decided to focus on this new business development. The financial results for periods prior to the abandonment of the previous business line have been reflected in the accompanying statement of operations as discontinued operations as this change represented a strategic shift in our business that had a major effect on our operations and financial results. Risks and Uncertainties Our business and our forward-looking statements involve substantial known and unknown risks and uncertainties, including the risks and uncertainties inherent in our statements regarding the impacts of COVID-19, or other future pandemics on our business, results of operations, financial position, and cash flows. The Company has a lack of revenue history and has had a limited history of operations. No revenue has historically been derived from the assets purchased. Regenerex can give no assurance of success or profitability to the Company’s investors. The wound care healing space is well suited for Home Care service providers that are funded by the US Government. The majority of manufacturing and distribution will be outsourced. However, strategic planning and development will be performed internally by the Company.

BASIS OF PRESENTATION OF INTERI

BASIS OF PRESENTATION OF INTERIM FINANCIAL STATEMENTS	9 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
BASIS OF PRESENTATION OF INTERIM FINANCIAL STATEMENTS	NOTE 2 – BASIS OF PRESENTATION OF INTERIM FINANCIAL STATEMENTS The Company prepares its financial statements in accordance with accounting principles generally accepted in the United States of America. The accompanying interim unaudited financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X. In our opinion, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the nine months ended December 31, 2022, are not necessarily indicative of the results that may be expected for the year ending March 31, 2023. Notes to the unaudited interim financial statements that would substantially duplicate the disclosures contained in the audited financial statements for the year ended March 31, 2022, have been omitted. This report should be read in conjunction with the audited financial statements and the footnotes thereto for the fiscal year ended March 31, 2022, included within the Company’s Annual Report on Form 10-K as filed with the Securities and Exchange Commission.

GOING CONCERN

GOING CONCERN	9 Months Ended
	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GOING CONCERN	NOTE 3 – GOING CONCERN These financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”), which contemplate the continuation of the Company as a going concern. The Company has incurred losses from operations, and as of December 31, 2022, it had excess liabilities over assets of $1,076,657. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The Company requires significant cash to launch its business and reduce its payable. Management’s plans are to actively seek capital to enable the Company to add new products and/or services to ultimately achieve profitability. However, management cannot provide assurance that they can raise sufficient capital and whether the Company will ultimately achieve profitability, become cash flow positive, or raise additional debt and/or equity capital. If the Company is unable to raise additional capital in the near future or meet financing requirements, management expects that the Company will need to curtail operations, seek additional capital on less favorable terms, and/or pursue other remedial measures. These financial statements do not include any adjustments related to the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary should the Company become unable to continue as a going concern.

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	NOTE 4 –SIGNIFICANT ACCOUNTING POLICIES Revenue Recognition The Company will record revenue under ASC 606 by 1) identifying the contract with the customer 2) identifying the performance obligations in the contract 3) determining the transaction price, 4) allocating the transaction price to the required performance obligations in the contract, and 5) recognizing revenue when or as the companies satisfies a performance obligation. We expect to generate revenue from home care service providers that are funded by the U.S. Government. The Company defers revenue where the earnings process is not yet complete. To date, no revenue has been generated from the asset acquisition disclosed in Note 1. Earnings per Share Earnings per share is reported in accordance with FASB Topic 260 “ Earnings per Share December 31 , 2022, and 2021, the Company does not have any common share equivalents outstanding. Website Expenditures related to the planning and operation of the Company’s website are expensed as incurred. Expenditures related to the website application and infrastructure development are capitalized and amortized over the website’s estimated useful life of three (3) years. Amortization expense for the three and nine months ended December 31, 2022 and 2021 was $723 and $2,516 and $1,016 and $2,329, respectively. Computer Equipment Expenditures related to the maintenance of the Company’s computer equipment are expensed as incurred. Purchase of computer equipment with cost over $500 are capitalized and amortized over the computer’s estimated useful life of three (3) years. Amortization expense for the three and nine months ended December 31, 2022, and 2021 was $82 and $82 and $0 and $0 respectively. Recent Accounting Pronouncements The Financial Accounting Standards Board issued Accounting Standards Updates (“ASU”) to amend the authoritative literature in the Accounting Standards Codification (“ASC”). There have been a number of ASUs to date that amend the original text of the ASC. The Company believes those updates issued-to-date either (i) provide supplemental guidance, (ii) are technical corrections, (iii) are not applicable to the Company, or (iv) are not expected to have a significant impact on the Company.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	9 Months Ended
	Dec. 31, 2022
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 5 – RELATED PARTY TRANSACTIONS The Company purchased assets from the Company’s current Chief Executive Officer (“CEO”) and Secretary/Treasurer (see note 6). Related Party Advances During the nine-month period ended December 31, 2022, the Company’s Chief Financial Officer (“CFO”) and the Company’s Chief Executive Officer (“CEO”) advanced the Company monies for operating expenses in the amount of $200. The related party advances totaled $131,887 and $131,687 as of December 31, 2022, and March 31, 2022, respectively. The related party advances accrue interest at ten (10) percent per annum. Interest expense was $9,922 and $9,879 during the nine-month periods ended December 31, 2022, and 2021, respectively. Notes Payable to Related Parties On July 29, 2022, the Company’s Chief Financial Officer (“CFO”) and the Company’s Chief Executive Officer (“CEO”) were issued a promissory note in the principal amount of $7,500 for monies advanced for operating expenses. November 13, 2022, a partial repayment of $2,500 was made by the Company. The balance outstanding on December 31, 2022, is $5,000 and accrues interest at ten (10) percent per annum with repayment due no later than July 29, 2024. On November 4, 2022, an additional promissory note was issued to the CFO and the CEO in the amount of $33,000 with repayment due no later than November 4, 2024. Interest expense was $890 and $0 during the nine-month periods ended December 31, 2022, and 2021, respectively. Note Payables to Shareholders As at December 31, 2022 and March 31, 2022, the Company had various promissory notes with total outstanding principal balances of $511,081 and $493,366, respectively, due to a shareholder of the Company. These notes are unsecured, bear interest at 10% per annum, and have maturity dates ranging from January 4, 2023, to December 30, 2024. During the nine months ended December 31, 2022, notes with principal amounts totaling approximately $35,000 ($46,500 Canadian Funds) that came due during the period were reissued in the total principal amount of approximately $46,000 ($55,800 Canadian Funds) which included the principal amount plus accrued interest of approximately $7,000 ($9,300 Canadian Funds). During the nine months ended December 31, 2022, a note with principal amount of $1,074 that came due November 22, 2022, was reissued in the principal amount of $1,289 which included the principal amount plus accrued interest of $215. The reissued notes are unsecured, bear interest at 10% per annum, and have revised maturity dates ranging from May 20, 2024, to December 30, 2024. During the nine-month period ended December 31, 2022, a shareholder was issued additional three (3) promissory notes totaling $34,901. These notes are unsecured and bear interest at ten (10) percent per annum with principal and interest due twenty-four (24) months after the date of issue. Total accrued interest on notes payable to shareholder and related parties and related party advances was $116,901 and $74,748 as of December 31, 2022, and March 31, 2022, respectively, which is included in other accrued liabilities.

INTANGIBLE ASSETS AND INTELLECT

INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY	9 Months Ended
	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY	NOTE 6 – INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY On November 15, 2021, the Company entered into an Asset Purchase Agreement in which the Company purchased certain intellectual property in exchange for 150,000,000 shares of the Company’s common stock and up to $10,000,000 in contingent consideration to be paid at the rate of 15% of all gross revenues received from sales or investment money into the Company, payable on the 15th of the following month, for a period of 60 months. The Company will receive all rights and title to proprietary wound healing technologies platforms and formulas involving the application of wound care protocols to treat all wounds, such as diabetic ulcers, pressure ulcers, burns and surgical wounds. These unique products strategically position the Company to enter and capture a high proportionate market share in the U.S. The Technology Platforms include but are not limited to: A. B. C. D. E. F. G. H. I. J. K. Products: 1. 2. 3.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 7 – COMMITMENTS AND CONTINGENCIES The Company is not currently involved with and does not have knowledge of any pending or threatened litigation against the Company or any of its officers. See Note 6 for discussion of the $10,000,000 in contingent consideration to be paid in connection with the November 15, 2021 Asset Purchase Agreement. To date, no amounts have been payable under this agreement.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Dec. 31, 2022
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 8 – SUBSEQUENT EVENTS On January 4, 2023, one note to a shareholder that was originally due on January 4, 2023, with a principal amount of approximately $400 ($500 Canadian Funds) was reissued in the principal amount of approximately $450 ($600 Canadian Funds) which included the original principal amount plus interest accrued as at January 4, 2023 in the amount of approximately $80 ($100 Canadian Funds). Repayment of the note is due no later than January 4, 2025. On January 5, 2023, one note to a shareholder that was originally due on January 5, 2023, with a principal amount of approximately $400 ($500 Canadian Funds) was reissued in the principal amount of approximately $450 ($600 Canadian Funds) which included the original principal amount plus interest accrued as at January 5, 2023 in the amount of approximately $80 ($100 Canadian Funds). Repayment of the note is due no later than January 5, 2025. On January 11, 2023, one note to a shareholder that was originally due on January 5, 2023, with a principal amount of approximately $800 ($1,000 Canadian Funds) was reissued in the principal amount of approximately $900 ($1,200 Canadian Funds) which included the original principal amount plus interest accrued as at January 11, 2023 in the amount of approximately $150 ($200 Canadian Funds). Repayment of the note is due no later than January 11, 2025.

SIGNIFICANT ACCOUNTING POLICI_2

SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Revenue Recognition	Revenue Recognition The Company will record revenue under ASC 606 by 1) identifying the contract with the customer 2) identifying the performance obligations in the contract 3) determining the transaction price, 4) allocating the transaction price to the required performance obligations in the contract, and 5) recognizing revenue when or as the companies satisfies a performance obligation. We expect to generate revenue from home care service providers that are funded by the U.S. Government. The Company defers revenue where the earnings process is not yet complete. To date, no revenue has been generated from the asset acquisition disclosed in Note 1.
Earnings per Share	Earnings per Share Earnings per share is reported in accordance with FASB Topic 260 “ Earnings per Share December 31 , 2022, and 2021, the Company does not have any common share equivalents outstanding.
Website	Website Expenditures related to the planning and operation of the Company’s website are expensed as incurred. Expenditures related to the website application and infrastructure development are capitalized and amortized over the website’s estimated useful life of three (3) years. Amortization expense for the three and nine months ended December 31, 2022 and 2021 was $723 and $2,516 and $1,016 and $2,329, respectively.
Computer Equipment	Computer Equipment Expenditures related to the maintenance of the Company’s computer equipment are expensed as incurred. Purchase of computer equipment with cost over $500 are capitalized and amortized over the computer’s estimated useful life of three (3) years. Amortization expense for the three and nine months ended December 31, 2022, and 2021 was $82 and $82 and $0 and $0 respectively.
Recent Accounting Pronouncements	Recent Accounting Pronouncements The Financial Accounting Standards Board issued Accounting Standards Updates (“ASU”) to amend the authoritative literature in the Accounting Standards Codification (“ASC”). There have been a number of ASUs to date that amend the original text of the ASC. The Company believes those updates issued-to-date either (i) provide supplemental guidance, (ii) are technical corrections, (iii) are not applicable to the Company, or (iv) are not expected to have a significant impact on the Company.

NATURE OF OPERATIONS (Details N

NATURE OF OPERATIONS (Details Narrative) - USD ($)	9 Months Ended
	Dec. 31, 2022	Nov. 15, 2021
Entity Incorporation, Date of Incorporation	Nov. 18, 2005
Asset Acquisition, Contingent Consideration, Liability		$ 10,000,000
Purchase Intellectual Property [Member]
Shares, Issued		150,000,000

SIGNIFICANT ACCOUNTING POLICI_3

SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021
Accounting Policies [Abstract]
Amortization of Intangible Assets	$ 723	$ 1,016	$ 2,516	$ 2,329
Other Depreciation and Amortization	$ 82	$ 0	$ 82	$ 0

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	3 Months Ended	9 Months Ended
	Dec. 31, 2022	Dec. 31, 2022	Dec. 31, 2021	Nov. 04, 2022	Jul. 29, 2022	Mar. 31, 2022
Related Party Transaction [Line Items]
Due to Related Parties, Current	$ 131,887	$ 131,887				$ 131,687
Interest Expense, Related Party		9,922	$ 9,879
Repayments of Secured Debt		$ 2,500
Debt Instrument, Maturity Date Range, Start		Jan. 04, 2023
Debt Instrument, Maturity Date Range, End		Dec. 30, 2024
Interest Costs Incurred		$ 7,000
Accounts Payable, Interest-Bearing	$ 116,901	$ 116,901				74,748
July 292022 Note [Member]
Related Party Transaction [Line Items]
Debt Instrument, Face Amount					$ 7,500
Long-Term Debt, Gross					$ 5,000
Debt Instrument, Maturity Date		Jul. 29, 2024
Nov 42022 Note [Member]
Related Party Transaction [Line Items]
Long-Term Debt, Gross				$ 33,000
Debt Instrument, Maturity Date	Nov. 04, 2024
Note Payable To Related Parties [Member]
Related Party Transaction [Line Items]
Interest Expense, Related Party		$ 890	$ 0
A Note [Member]
Related Party Transaction [Line Items]
Debt Instrument, Repurchased Face Amount	$ 1,074	1,074
Debt Instrument, Repurchase Amount	$ 1,289	1,289
Interest Costs Incurred		$ 215
Reissued Notes [Member]
Related Party Transaction [Line Items]
Debt Instrument, Maturity Date Range, Start		May 20, 2024
Promissory Notes 2022 [Member]
Related Party Transaction [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	10%	10%
Debt Instrument, Description		a shareholder was issued additional three (3) promissory notes totaling $34,901
Chief Financial Officer [Member]
Related Party Transaction [Line Items]
Due to Related Parties, Current	$ 200	$ 200
Note Payable To Shareholder [Member]
Related Party Transaction [Line Items]
Long-Term Debt, Fair Value	$ 511,081	$ 511,081				$ 493,366
Debt Instrument, Interest Rate, Stated Percentage	10%	10%
Debt Instrument, Repurchased Face Amount	$ 35,000	$ 35,000
Debt Instrument, Repurchase Amount	$ 46,000	$ 46,000
Debt, Weighted Average Interest Rate	10%	10%
Note Payable To Shareholder Reissued Debt [Member]
Related Party Transaction [Line Items]
Debt Instrument, Maturity Date Range, End		Dec. 30, 2024

INTANGIBLE ASSETS AND INTELLE_2

INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY (Details Narrative)	1 Months Ended
	Nov. 15, 2021 shares
Goodwill and Intangible Assets Disclosure [Abstract]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	150,000,000
Business Combination, Contingent Consideration Arrangements, Description	up to $10,000,000 in contingent consideration to be paid at the rate of 15% of all gross revenues received from sales or investment money into the Company, payable on the 15th of the following month, for a period of 60 months

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative)	9 Months Ended
	Dec. 31, 2022 USD ($)
Short-Term Debt [Line Items]
Interest Costs Incurred	$ 7,000
Subsequent Event Note 1 [Member]
Short-Term Debt [Line Items]
Debt Instrument, Repurchase Date	Jan. 04, 2023
Debt Instrument, Repurchased Face Amount	$ 400
Debt Instrument, Repurchase Amount	450
Interest Costs Incurred	$ 80
Debt Instrument, Maturity Date, Description	Repayment of the note is due no later than January 4, 2025
Subsequent Event Note 2 [Member]
Short-Term Debt [Line Items]
Debt Instrument, Repurchase Date	Jan. 05, 2023
Debt Instrument, Repurchased Face Amount	$ 400
Debt Instrument, Repurchase Amount	450
Interest Costs Incurred	$ 80
Debt Instrument, Maturity Date, Description	Repayment of the note is due no later than January 5, 2025
Subsequent Event Note 3 [Member]
Short-Term Debt [Line Items]
Debt Instrument, Repurchase Date	Jan. 11, 2023
Debt Instrument, Repurchased Face Amount	$ 800
Debt Instrument, Repurchase Amount	900
Interest Costs Incurred	$ 150
Debt Instrument, Maturity Date, Description	Repayment of the note is due no later than January 11, 2025

Uncategorized Items - ixform10q

Label	Element	Value
Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture	us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation